Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1IFS2
|
|||
| Drug Name |
GFB-887
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
| Company |
Goldfinch Bio Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Short transient receptor potential channel 5 (TRPC5) | Target Info | Inhibitor | [2] |
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Reactome | TRP channels | |||
| Role of second messengers in netrin-1 signaling | ||||
| WikiPathways | Netrin-1 signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04387448) A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease. U.S.National Institutes of Health. | |||
| REF 2 | Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney Int Rep. 2021 Jul 23;6(10):2575-2584. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.